Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodger L Bick

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|June 19, 2003
Management of thrombotic and cardiovascular disorders in the new milleniumJawed Fareed, Debra A Hoppensteadt, Rodger L Bick
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 31, 2006
Pitfalls in warfarin therapyHarry L Messmore, Jawed Fareed, Rodger L Bick
Seminars in Thrombosis and Hemostasis|April 16, 2004
Epilogue. Expanded role of low-molecular-weight heparins in hematology and oncologyDebra A Hoppensteadt, Jawed Fareed, Rodger L Bick
Hematology/Oncology Clinics of North America|January 22, 2008
Controversies and unresolved issues in antiphospholipid syndrome pathogenesis and managementWilliam F Baker, Rodger L Bick, Jawed Fareed
Hematology/Oncology Clinics of North America|March 12, 2003
Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other adverse effects of heparin-type therapyJeanine M Walenga, Eugene P Frenkel, Rodger L Bick
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 29, 2008
Antigenic (immunogenic) profiling of bovine thrombin and its purified formsJeanine M Walenga, Rodger L Bick, Harry L Messmore
Hematology/Oncology Clinics of North America|March 12, 2003
Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiationDebra Hoppensteadt, Jeanine M Walenga, Jawed Fareed, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 2, 2009
Comparison of immunogenic potentials of bovine thrombin preparationsHe Zhu, Debra Hoppensteadt, Cafer Adiguzel, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 26, 2005
Argatroban and lepirudin: clinical trials to clinical practiceHarry L Messmore, Jawed Fareed, Jeanine M Walenga, et al.
Hematology/Oncology Clinics of North America|January 11, 2005
Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical useRodger L Bick, Eugene P Frenkel, Jeanine Walenga, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|June 19, 2003
Management of thrombotic and cardiovascular disorders in the new milleniumJawed Fareed, Debra A Hoppensteadt, Rodger L Bick
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 31, 2006
Pitfalls in warfarin therapyHarry L Messmore, Jawed Fareed, Rodger L Bick
Seminars in Thrombosis and Hemostasis|April 16, 2004
Epilogue. Expanded role of low-molecular-weight heparins in hematology and oncologyDebra A Hoppensteadt, Jawed Fareed, Rodger L Bick
Hematology/Oncology Clinics of North America|January 22, 2008
Controversies and unresolved issues in antiphospholipid syndrome pathogenesis and managementWilliam F Baker, Rodger L Bick, Jawed Fareed
Hematology/Oncology Clinics of North America|March 12, 2003
Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other adverse effects of heparin-type therapyJeanine M Walenga, Eugene P Frenkel, Rodger L Bick
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 29, 2008
Antigenic (immunogenic) profiling of bovine thrombin and its purified formsJeanine M Walenga, Rodger L Bick, Harry L Messmore
Hematology/Oncology Clinics of North America|March 12, 2003
Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiationDebra Hoppensteadt, Jeanine M Walenga, Jawed Fareed, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 2, 2009
Comparison of immunogenic potentials of bovine thrombin preparationsHe Zhu, Debra Hoppensteadt, Cafer Adiguzel, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 26, 2005
Argatroban and lepirudin: clinical trials to clinical practiceHarry L Messmore, Jawed Fareed, Jeanine M Walenga, et al.
Hematology/Oncology Clinics of North America|January 11, 2005
Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical useRodger L Bick, Eugene P Frenkel, Jeanine Walenga, et al.
Pageof 5